Eligible AACR 2019 Annual Meeting Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

New Treatment Approaches for Breast and Ovarian Cancer

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 7 of 7
A phase Ib study of miransertib (ARQ 092) in combination with anastrozole in patients with PIK3CA or AKT1-mutant ER+ endometrial or ovarian cancer.
Vicky Makker
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:00 PM
Targeting MUC16 with the THIOMABTM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: A phase I expansion study
Kathleen Moore
University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:00 PM
Phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)
Khanh T Do
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:00 PM
OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
Mark E Robson
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:00 PM
Cyclin E1 (CCNE1) expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial
Nicholas C. Turner
Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:00 PM
MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2- advanced breast cancer - Results from the preplanned final PFS analysis
Matthew P Goetz
Mayo Clinic, Rochester, MN, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:00 PM
Primary results from FAIRLANE (NCT02301988), a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (eTNBC)
Mafalda Oliveira
Vall d'Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 7 of 7